Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.97 |
| ▸ | TK2 | O00142 | 2/20 | 0.68 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.56 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.52 |
| ▸ | TYMP | P19971 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6758925 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL19657168 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2579064 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL309063 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL654693 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL12143148 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL158910 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15810788 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Phosphoric Acid SCHEMBL9804833 | 0.95 | PYGM (0.88) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Phosphoric Acid SCHEMBL3515238 | 0.95 | PYGM (0.88) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12146 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740010-A1 | NEGATIVE TUNE STANDARD FOR MASS SPECTROMETRY | Agilent Technologies, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | claimed |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| US-12577554-B2 | Methods for purification of messenger RNA | TRANSLATE BIO, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-20260028616-A1 | METHODS AND APPARATUS FOR DUPLEX NUCLEOTIDE PURIFICATION | AGILENT TECHNOLOGIES, INC. (US) | 2026-01-29 | — | — | US | claimed |
| EP-4677078-A1 | MANUFACTURE OF MESSENGER RNA WITH KP34 POLYMERASE | Sanofi Pasteur Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | claimed |
| EP-4665405-A1 | DNA COMPOSITIONS COMPRISING MODIFIED URACIL | Flagship Pioneering Innovations VII, LLC (US) | 2025-12-24 | — | — | EP | claimed |
| EP-0828750-A1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | NeXstar Pharmaceuticals, Inc. (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1997035591-A9 | METHOD OF TREATING CILIARY DYSKINESIA WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS | — | 1998-02-19 | — | — | WO | claimed |
| WO-1998003182-A2 | USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS | INSPIRE PHARMACEUTICALS, INC. (US) | 1998-01-29 | — | — | WO | claimed |
| WO-1998003177-A1 | METHOD OF TREATING SINUSITIS WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 1998-01-29 | — | — | WO | claimed |
| WO-1997035591-A2 | METHOD OF TREATING CILIARY DYSKINESIA WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1996040059-A1 | DINUCLEOTIDES USEFUL FOR THE TREATMENT OF LUNG DISEASE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996038460-A1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | claimed |
| EP-0653439-A2 | Stabilized oligonucleotids and the use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-17 | — | — | EP | claimed |
| US-4529700-A | Hybridoma cells secreting a monoclonal antibody specific for 5-bromo and 5-iodoeoxyuridine and reagents for measuring cellular proliferation | UNIVERSITY OF MIAMI (US) | 1985-07-16 | — | — | US | claimed |
| EP-0102228-A2 | Hybridoma secreting a monoclonal antibody specific for 5-bromo and 5-iododeoxyuridine and reagent for measuring cellular proliferation | UNIVERSITY OF MIAMI (US) | 1984-03-07 | — | — | EP | claimed |